284. Diamond-Blackfan anemia Clinical trials / Disease details
Clinical trials : 36 / Drugs : 95 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-006322-25-IT (EUCTR) | 20/08/2012 | 03/09/2012 | Extension to the treatment of iron overload with chelation therapy | A PHASE 3, OPEN-LABEL, MILTICENTRE, EXTENSION SAFETY AND TOLERABILITY STUDY FOR TRANSFUSIONALLY IRON OVERLOADED CHILDRE, ADOLISCENTS AND ADULTS USING FBS0701 (SSP-004184) - SPD602-301 (FBS0701 - CTP - 15) | ADULT PATIENTS SUFFERING FROM IRON OVERLOAD OF TRANSFUSION-DEPENDENT DOCUMENTED, IN WHICH THE FOLLOWING PRIMARY DIAGNOSIS: ANEMIA HEREDITARY (EG sickle cell anemia), thalassemia and Diamond-Blackfan anemia MedDRA version: 15.0;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: FBS0701 CAPSULE Product Code: FBS0701/SSP004184 INN or Proposed INN: iron chelating agents Product Name: FBS0701 CAPSULE Product Code: FBS0701/SSP004184 INN or Proposed INN: IRON CHELATING AGENTS Product Name: FBS0701 CAPSULE Product Code: FBS0701/SSP004184 INN or Proposed INN: IRON CHELATING AGENTS Product Name: FBS0701 CAPSULE Product Code: FBS0701/SSP004184 INN or Proposed INN: IRON CHELATING AGENTS Product Name: FBS0701 CAPSULE Product Code: FBS0701 INN or Proposed INN: IRON CHELATING AGENTS Product Name: FBS0701 CAPSULE Product Code: FBS0701/SSP004184 INN or Proposed INN: IRON CHELATING AGENTS | FERROKIN BIOSCIENCES INC. | NULL | Not Recruiting | Female: yes Male: yes | 1500 | Phase 3 | United States;United Kingdom;Italy | ||
| 2 | EUCTR2011-005675-16-IT (EUCTR) | 15/05/2012 | 02/08/2012 | Treatment of chronic iron overload with a chelation therapy (FBS0701) | A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two FBS0701 Doses in the Treatment of Chronic Iron Overload Requiring Chelation Therapy - FBS0701 in the treatment of chronic iron overload | Patients with transfusional iron overload, with the following primary diagnosis:hereditary anemia (such as sickle cell disease),ß-thalassemia and Diamond Blackfan anemia;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: FBS0701 CAPSULE Product Code: FBS0701 INN or Proposed INN: iron chelating agents Product Name: FBS0701 CAPSULE Product Code: FBS0701 INN or Proposed INN: Iron chelating agents Product Name: FBS0701 CAPSULE Product Code: FBS0701 INN or Proposed INN: Iron chelating agents Product Name: FBS0701 CAPSULE Product Code: FBS0701 INN or Proposed INN: iron chelating agents Product Name: FBS0701 CAPSULE Product Code: FBS0701 INN or Proposed INN: iron chelating agents | FERROKIN BIOSCIENCES INC. | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | United States;Canada;Lebanon;Turkey;Italy |